
Abivax SA (ABVX) Stock Forecast & Price Target
Abivax SA (ABVX) Analyst Ratings
Bulls say
Abivax SA is poised for significant growth due to promising Phase 3 clinical trial results for its drug candidate, obefazimod, which has demonstrated efficacy and safety that align with regulatory expectations. The company's ability to meet co-primary endpoints and its increased peak sales estimates, driven by a refined understanding of market penetration, suggest a multi-billion-dollar revenue potential in addressing chronic inflammatory diseases like ulcerative colitis. Additionally, the rapid therapeutic effect of obefazimod, particularly in refractory patients, underscores its strong value proposition in a market with substantial unmet medical needs.
Bears say
Abivax SA faces significant challenges in translating promising induction trial results for its drug candidate obefazimod into compelling maintenance efficacy, a concern echoing previous failures with similar therapies from other companies. The company has a history of financial losses and lacks a proven path to profitability, which further raises doubts about its market viability, especially given that previous oral therapies have not succeeded in the inflammatory bowel disease sector. Additionally, the risks associated with the drug's efficacy and potential partnership hurdles contribute to an overall negative outlook on its ability to successfully commercialize obefazimod.
This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.
Abivax SA (ABVX) Analyst Forecast & Price Prediction
Start investing in Abivax SA (ABVX)
Order type
Buy in
Order amount
Est. shares
0 shares